Henry Schein, Inc. reports developments across its health care distribution, practice solutions, and dental technology businesses. The company serves office-based dental and medical practitioners, dental laboratories, government and institutional health care clinics, and other alternate care sites through business, clinical, technology, and supply chain solutions.
Recurring news themes include earnings releases, financial guidance, investor conference participation, board and executive governance updates, and product announcements from Henry Schein One. Recent technology coverage centers on Dentrix Ascend, a cloud-based dental platform that integrates practice management, clinical workflows, imaging, revenue cycle management, analytics, patient experience tools, and AI-enabled workflow capabilities.
Henry Schein Medical (Nasdaq: HSIC) celebrated National Girls and Women in Sports Day 2025 by launching a video featuring four prominent WNBA athletic trainers. The video highlights Theresa Acosta (New York Liberty), Dr. Christina Kennedy (Washington Mystics), Natalie Trotter (Women's Professional Basketball Athletic Trainers Association), and Brittanie Vaughn (Seattle Storm).
The interviews explore their memorable career moments, the increasing presence of women in sports, and career advice. This marks the third year of Henry Schein Medical's Athletics and Schools business producing videos celebrating women athletic trainers, having featured 14 women ATs from three professional sports leagues to date.
The initiative aims to recognize athletic trainers' important role in athlete care and highlight the growing representation of women in sports medicine. In 2024, the company featured athletic trainers from five NBA teams.
Henry Schein (HSIC) announced a strategic investment from KKR, which will become the company's largest non-index fund shareholder with a 12% position through a $250 million investment. KKR can increase its stake to 14.9% through open market purchases.
The company reported preliminary Q4 2024 results with revenue of $3.2 billion and full-year 2024 revenue of $12.7 billion. Q4 GAAP EPS was $0.74, while non-GAAP EPS reached $1.19. Full-year 2024 GAAP EPS was $3.05, with non-GAAP EPS at $4.74.
For 2025, Henry Schein projects low to mid-single digit growth in both revenues and non-GAAP EPS. The company also announced a $500 million increase to its share repurchase program, with $250 million to be executed through accelerated share repurchases.
Henry Schein (NASDAQ: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, has announced its upcoming fourth quarter and full-year 2024 financial results release and conference call.
The company will release its financial results before market opening on Tuesday, February 25, 2025. A live webcast earnings conference call will follow at 8:00 a.m. Eastern time. The call will feature presentations from Stanley M. Bergman, Chairman of the Board and CEO, and Ronald N. South, Senior Vice President and CFO.
Investors can access the webcast through the company's investor relations website at https://investor.henryschein.com/webcasts. A replay of the presentation will be made available on the website afterward.
Henry Schein (HSIC) has completed the acquisition of substantially all assets of Acentus, a national medical supplier specializing in Continuous Glucose Monitors (CGMs). The deal, initially announced on November 20, 2024, brings Acentus founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia into Henry Schein's team, incorporating their healthcare industry and product expertise.
The transaction was facilitated by Provident Healthcare Partners, with their deal team led by Managing Director Kevin Palamara. Robinson & Cole provided legal counsel to Acentus during the acquisition process. Acentus has developed a distinctive CGM platform that has shown significant growth since its establishment.
Henry Schein (Nasdaq: HSIC) has completed the acquisition of Acentus, a Tampa-based national medical supplier specializing in Continuous Glucose Monitors (CGMs) with annual revenue of approximately $35 million. The transaction is expected to be neutral to 2025 non-GAAP earnings per share and accretive thereafter.
This acquisition follows Henry Schein's previous acquisitions of Prism Medical Products (2021), Shield Healthcare, and Mini Pharmacy (2023), strengthening its position in the homecare medical supplies market. With the addition of Acentus, Henry Schein's homecare medical products platform will now have an annual revenue base exceeding $350 million.
The four Acentus founders will join Henry Schein, bringing their expertise in the product category and healthcare industry. The acquisition aims to enhance Henry Schein's ability to serve customers through direct CGM product delivery to patients' homes.
Henry Schein (Nasdaq: HSIC) has announced the opening of the Henry Schein Cares Foundation 2025 Relief Fund to support Los Angeles area fires relief efforts. The initiative includes a total commitment of up to $300,000, comprising:
- $25,000 each from the Company and Foundation
- Up to $50,000 in matching Team Schein Member contributions
- Up to $150,000 in essential healthcare supplies
The company has established a Customer Emergency Support Hotline (800-999-9729) for affected dental and medical professionals. The initiative aims to provide critical healthcare supplies and resources to communities impacted by the wildfires, working with trusted relief and recovery charitable partners.
Henry Schein (NASDAQ: HSIC) has activated its Customer Emergency Support Hotline at 800-999-9729 to assist dental and medical professionals affected by the ongoing California fires. The hotline provides 24/7 support, with live assistance from Team Schein Members available from 8 a.m. to 8 p.m. Eastern Time.
The company offers resources to help practitioners manage operational, logistical, and financial challenges resulting from the natural disaster. These include an Emergency Preparedness Guide to minimize disaster impact and an Emergency Recovery Guide to assist in practice rebuilding efforts.
Henry Schein (HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, has announced its participation in J.P. Morgan's Healthcare Investor Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 3:00 p.m. PST / 6:00 p.m. EST at The Westin St. Francis Hotel in San Francisco. Investors and interested parties can access the live webcast through www.henryschein.com/IRwebcasts, with replay options available on the company's website after the presentation.
Henry Schein (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, has announced its participation in two major investor conferences this December. The company will present at Piper Sandler's Healthcare Conference in New York on December 4, 2024, at 11:00 a.m. Eastern time, and at the Evercore ISI HealthCONx Conference in Coral Gables, Florida, on December 5, 2024, at 9:10 a.m. Eastern time. Both presentations will be available via live webcast on the company's website, with replays accessible afterward.
Henry Schein (NASDAQ: HSIC) has signed an agreement to acquire Acentus, a national medical supplier specializing in Continuous Glucose Monitors (CGMs) with annual revenue of $35 million. This acquisition follows Henry Schein's previous acquisitions of Prism Medical Products, Shield Healthcare, and Mini Pharmacy, expanding their homecare medical products platform to an annual revenue base of approximately $350 million. The transaction is expected to be neutral to 2024 non-GAAP earnings per share, accretive thereafter, and close in Q1 2025. Acentus's founders will join Henry Schein post-acquisition.